Dublin, April 21, 2022 (GLOBE NEWSWIRE) -- The "Osteosarcoma Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2021-2027" report has been added to ResearchAndMarkets.com's offering.
This reports provides a data-driven overview of the current and future competitive landscape in osteosarcoma therapeutics.
In osteosarcoma Cells expressing ganglioside GD2 is a major focus of drug developers. There are 131 drugs in the pipeline with 98% molecules present in early-to-mid stage. Mid-sized Pharma dominates clinical development in this space.
More frequent use of newer symptomatic treatments are expected to drive the market. However, the market growth is limited by higher usage of generic medicines, and due to high cost associated with osteosarcoma therapies.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
- Develop business strategies by understanding the trends shaping and driving the osteosarcoma market
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global osteosarcoma market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships
Key Topics Covered:
1 Preface
1.1 Table of Contents
1.2 Abbreviations
1.3 Related Reports
1.4 Upcoming Related Reports
2 Executive Summary
2.1 Key Findings
2.2 Key Events
3 Introduction
3.1 Report Scope
3.2 Disease Overview Epidemiology Overview
3.3 Epidemiology
4 Marketed Drugs Assessment
4.1 Marketed Drugs Overview
5 Pipeline Assessment
5.1 Pipeline Overview
5.2 Pipeline Breakdown by Region
5.3 Pipeline Breakdown by Molecule Type and Target
5.4 Drug Review Designations
5.5 Phase Transition Success Rates
5.6 Likelihood of Approval
6 Clinical Trial Assessment
6.1 Clinical Trials Overview by Phase
6.2 Overview by Region
6.4 Therapy Area Perspective
6.4 Leading Sponsors
6.5 Enrollment Analytics
6.6 Feasibility Analysis
7 Commercial Assessment
7.1 Upcoming Market Catalysts
For more information about this report visit https://www.researchandmarkets.com/r/rqowxu
